NDA 206940 · Abbvie
Viberzi
Eluxadoline · Oral · mu-Opioid Receptor Agonist
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 17, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
May 27, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
10
4 Phase 3, 1 recruiting
FAERS reports
2,949
1,137 serious, 69 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 16, 2024.
VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D). VIBERZI is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D). ( 1 )
Mechanism: Eluxadoline is a mu-opioid receptor agonist; eluxadoline is also a delta opioid receptor antagonist and a kappa opioid receptor agonist. The binding affinities (Ki) of eluxadoline for the human mu and delta opioid receptors are 1.8 nM and 430 nM, respectively. The binding affinity (Ki) of eluxadoline for the human kappa opioid receptor has not been determined; however, the Ki for guinea pig cerebellum kappa opioid receptor is 55 nM. In animals, eluxadoline interacts with opioid receptors in the gut.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 27, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelSummary ReviewReview
2 products under this application
- VIBERZI · ELUXADOLINE 100MG · TABLET, ORAL · Prescription · TE AB
- VIBERZI · ELUXADOLINE 75MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Eluxadoline" as an intervention, any sponsor and status, largest first.
- Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)Pivotal-lookingCompleted
Furiex Pharmaceuticals, IncIndustry
NCT01553591 · 1,282 participants · Start May 29, 2012 · Primary completion Jul 29, 2014
Drug: Eluxadoline; Placebo · For: Irritable Bowel Syndrome
Sites: Athens, Alabama; Birmingham, Alabama; Foley, Alabama · 283 sites in all
- Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)Pivotal-lookingCompleted
Furiex Pharmaceuticals, IncIndustry
NCT01553747 · 1,146 participants · Start May 29, 2012 · Primary completion Jan 9, 2014
Drug: Eluxadoline; Placebo · For: Irritable Bowel Syndrome
Sites: Birmingham, Alabama; Decatur, Alabama; Huntsville, Alabama · 253 sites in all
- Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With DiarrheaPivotal-lookingCompleted
Furiex Pharmaceuticals, IncIndustry
NCT01130272 · 807 participants · Start Apr 28, 2010 · Primary completion Jul 14, 2011
Drug: Eluxadoline; Placebo · For: Irritable Bowel Syndrome
Sites: Anniston, Alabama; Birmingham, Alabama; Dothan, Alabama · 288 sites in all
- Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide UsePivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT02959983 · 346 participants · Start Oct 25, 2016 · Primary completion Jan 22, 2018
Drug: Eluxadoline; Placebo · For: Irritable Bowel Syndrome With Diarrhea
Sites: Huntsville, Alabama; Saraland, Alabama; Phoenix, Arizona · 83 sites in all
- Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in ChildrenPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03339128 · 272 participants · Start Nov 15, 2017 · Primary completion Aug 17, 2026
Drug: Eluxadoline; Placebo · For: Irritable Bowel Syndrome
Sites: Hot Springs, Arkansas; Little Rock, Arkansas; Corona, California · 46 sites in all
- Efficacy of Pregabalin for Patients With Irritable Bowel SyndromePivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07635394 · 258 participants (planned) · Start Apr 7, 2026 · Primary completion Apr 8, 2026
Drug: The pregabalin group; Routine Treatment · For: Irritable Bowel Syndrome (IBS)
Sites: Beijing, China
- A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)Pivotal-lookingEnrolling by invitation
AbbVieAbbVie (ABBV)
NCT04880876 · 124 participants (planned) · Start Aug 13, 2021 · Primary completion Dec 2032
Drug: 25mg Eluxadoline; 100mg Eluxadoline · For: Irritable Bowel Syndrome
Sites: Corona, California; Miami, Florida; Stockbridge, Georgia · 6 sites in all
AllerganAbbVie (ABBV)
NCT03441581 · 24 participants · Start Feb 23, 2018 · Primary completion Apr 28, 2020
Drug: Eluxadoline · For: Irritable Bowel Syndrome With Diarrhea
Sites: Rochester, Minnesota
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use364
- abdominal pain352
- diarrhoea348
- constipation283
- pancreatitis278
- nausea220
- drug ineffective218
- abdominal pain upper210
- inappropriate schedule of drug administration162
- vomiting137
- fatigue118
- dizziness108
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2015 | 3 |
| 2016 | 837 |
| 2017 | 724 |
| 2018 | 266 |
| 2019 | 318 |
| 2020 | 184 |
| 2021 | 116 |
| 2022 | 95 |
| 2023 | 116 |
| 2024 | 92 |
| 2025 | 120 |
| 2026 | 77 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Viberzi (Eluxadoline)
2024 spending
$59.2M
Beneficiaries
6,935
34,827 claims
Per beneficiary
$8,539
$26.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $60,194,815 |
| 2021 | $58,110,619 |
| 2022 | $59,159,196 |
| 2023 | $59,717,509 |
| 2024 | $59,221,425 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
Cash BD, Lacy BE, Schoenfeld PS, et al. · Am J Gastroenterol 2017 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.
Lacy BE, Chey WD, Cash BD, et al. · Am J Gastroenterol 2017 · Clinical Trial, Phase III, Multicenter Study
- Evaluation of Eluxadoline Effect on Cardiac Repolarization.
Bonifacio L, Hunt TL, McIntyre G, et al. · Clin Pharmacol Drug Dev 2018 · Clinical Trial, Phase I, Randomized Controlled Trial
- Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D: Additional post hoc analyses of Phase 3 trials.
Lembo AJ, Covington PS, Dove LS, et al. · Neurogastroenterol Motil 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
- Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
Lembo AJ, Lacy BE, Zuckerman MJ, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Multicenter Study
- Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS, Lembo A, Randall CW, et al. · Gastroenterology 2013 · Clinical Trial, Phase II, Multicenter Study
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.